Science Explorer Back to mapMap
Discussion
Company · Ann Arbor · United States

Esperion Therapeutics (United States)

Research works
74
▲ 79% vs 2018-21
Citations
4k
54.7 per fractional work
Top-10% rate
17.2%
all institutions 10.0%
Open access
44%
world 40%
International
33%
world 18%

Not ranked overall: Esperion Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Esperion Therapeutics (United States) work in?

In 2022-now, 73% of research at Esperion Therapeutics (United States) is in Health Sciences, 20% in Life Sciences. Its largest fields are Medicine (73%), Biochemistry, Genetics and Molecular Biology (14%), Immunology and Microbiology (5%). It does 2.4× the world's share of Health Sciences.

Health Sciences: 19 fractional works · 73.4% of its workMedicine: 18 fractional works · 72.6% of its workSurgery: 5 fractional works · 20.2% of its workOncology: 2 fractional works · 7.4% of its workRheumatology: 2 fractional works · 6.4% of its workEndocrinology, Diabetes and Metabolism: 2 fractional works · 5.9% of its workPhysiology: 1 fractional works · 4.6% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 4.4% of its workGenetics: 1 fractional works · 3.3% of its workNephrology: 1 fractional works · 2.9% of its workEmergency Medicine: 1 fractional works · 2.3% of its workEpidemiology: 1 fractional works · 2.2% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 2.1% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.7% of its workInfectious Diseases: 0 fractional works · 1.7% of its workNeurology: 0 fractional works · 1.5% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 1.3% of its workOphthalmology: 0 fractional works · 1.2% of its workFamily Practice: 0 fractional works · 1.0% of its workHepatology: 0 fractional works · 0.6% of its workGastroenterology: 0 fractional works · 0.6% of its workInternal Medicine: 0 fractional works · 0.3% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.3% of its workAnesthesiology and Pain Medicine: 0 fractional works · 0.2% of its workPharmacology: 0 fractional works · 0.2% of its workPsychiatry and Mental health: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 0.7% of its workNutrition and Dietetics: 0 fractional works · 0.7% of its workLife Sciences: 5 fractional works · 20.2% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 13.9% of its workMolecular Biology: 2 fractional works · 6.9% of its workCancer Research: 1 fractional works · 2.7% of its workClinical Biochemistry: 0 fractional works · 1.3% of its workGenetics: 0 fractional works · 1.3% of its workBiochemistry: 0 fractional works · 0.7% of its workBiotechnology: 0 fractional works · 0.7% of its workCell Biology: 0 fractional works · 0.3% of its workImmunology and Microbiology: 1 fractional works · 4.7% of its workImmunology: 1 fractional works · 4.7% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.2% of its workPharmaceutical Science: 0 fractional works · 0.9% of its workPharmacology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workAgricultural and Biological Sciences: 0 fractional works · 0.5% of its workPlant Science: 0 fractional works · 0.5% of its workPhysical Sciences: 1 fractional works · 4.8% of its workMathematics: 1 fractional works · 4.2% of its workAlgebra and Number Theory: 1 fractional works · 2.6% of its workMathematical Physics: 0 fractional works · 1.3% of its workStatistics and Probability: 0 fractional works · 0.2% of its workEngineering: 0 fractional works · 0.7% of its workBiomedical Engineering: 0 fractional works · 0.7% of its workSocial Sciences: 0 fractional works · 1.5% of its workEconomics, Econometrics and Finance: 0 fractional works · 1.2% of its workEconomics and Econometrics: 0 fractional works · 1.2% of its workBusiness, Management and Accounting: 0 fractional works · 0.3% of its workOrganizational Behavior and Human Resource Management: 0 fractional works · 0.3% of its workALL ITS WORKEsperionTherapeutics…25fractional works, 2022-now
Life Sciences20%Physical Sciences5%Health Sciences73%Social Sciences2%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 10 fields, with their numbers
    1. Medicine1872.6%
    2. Nursing00.7%
    1. Biochemistry, Genetics and Molecular Biology413.9%
    2. Immunology and Microbiology14.7%
    3. Pharmacology, Toxicology and Pharmaceutics01.2%
    4. Agricultural and Biological Sciences00.5%
    1. Mathematics14.2%
    2. Engineering00.7%
    1. Economics, Econometrics and Finance01.2%
    2. Business, Management and Accounting00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.10× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 2.60× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 4.64× its world share, 1 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 3.41× its world share, 0 worksPharmacology, Toxico…Engineering: 0.04× its world share, 0 worksEngineeringMathematics: 3.53× its world share, 1 worksMathematicsMedicine: 3.78× its world share, 18 worksMedicineNursing: 1.54× its world share, 0 worksNursingBusiness, Management and Accounting: 0.10× its world share, 0 worksBusiness, Management…Economics, Econometrics and Finance: 0.56× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 4.6×. Every wedge is a field page.

All 10 fields, with their numbers
  1. Immunology and Microbiology4.64×1 works
  2. Medicine3.78×18 works
  3. Mathematics3.53×1 works
  4. Pharmacology, Toxicology and Pharmaceutics3.41×0 works
  5. Biochemistry, Genetics and Molecular Biology2.60×4 works
  6. Nursing1.54×0 works
  7. Economics, Econometrics and Finance0.56×0 works
  8. Agricultural and Biological Sciences0.10×0 works
  9. Business, Management and Accounting0.10×0 works
  10. Engineering0.04×0 works

Who are the top researchers at Esperion Therapeutics (United States)?

Ranked on the quality score, LeAnne T. Bloedon, Roger S. Newton and Stephen L. Pinkosky lead among researchers whose main affiliation is Esperion Therapeutics (United States).

  1. 1 LeAnne T. Bloedon United States · #185,386 worldwide 7.3k citations · 82 works
  2. 2 Roger S. Newton United States · #227,966 worldwide 8k citations · 119 works
  3. 3 Stephen L. Pinkosky United States · #289,652 worldwide 2.5k citations · 28 works
  4. 4 Jeffrey Christian Hanselman United States · #314,896 worldwide 3k citations · 50 works
  5. 5 Diane Elaine MacDougall United States · #369,613 worldwide 2.8k citations · 63 works
  6. 6 Charles L. Bisgaier United States · #617,204 worldwide 5.3k citations · 71 works
  7. 7 Janice Rose Margulies United States · #650,292 worldwide 1.1k citations · 18 works
  8. 8 Sergey Ivanovich Filippov United States · #1,565,127 worldwide 1.8k citations · 41 works
  9. 9 Evelyn Sarnes United States · #1,815,352 worldwide 489 citations · 24 works
  10. 10 Clay T. Cramer United States · #1,909,053 worldwide 1.4k citations · 33 works
All ranked researchers at Esperion Therapeutics (United States)

What are the most cited papers from Esperion Therapeutics (United States)?

The most cited paper from Esperion Therapeutics (United States) is "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients" (Steven E. Nissen et al., 2023), with 951 citations. Next come "Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol" (815) and "Aromaticity as a Cornerstone of Heterocyclic Chemistry" (812).

Most cited papers
#PaperReleasedCitations
1 Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients Steven E. Nissen et al. · New England Journal of Medicine Open access 4 Mar 2023 951
2 Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol Kausik Kumar Ray, Harold Edward Bays, Alberico Luigi Catapano et al. · New England Journal of Medicine Open access 13 Mar 2019 815
3 Aromaticity as a Cornerstone of Heterocyclic Chemistry Alexandrù T. Balaban, Daniela Carmen Oniciu, ALAN ROY KATRITZKY · Chemical Reviews Review 17 Apr 2004 812
4 Methionine‐deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF‐I and insulin levels, and increases hepatocyte MIF levels and stress resistance Richard A. Miller, Gretchen Buehner, Yayi Chang et al. · Aging Cell Open access 13 Apr 2005 755
5 Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis Stephen L. Pinkosky, Roger S. Newton, Emily Anne Day et al. · Nature Communications Open access 28 Nov 2016 498
All 60 most cited papers, with filters and sorting

Which keywords describe research at Esperion Therapeutics (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Inflammation, Statins, Clinical Trials, Cardiovascular Disease Prevention, C-Reactive Protein, Cholesterol-lowering, LDL Cholesterol and Atherosclerosis.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 27 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 27 words, with their numbers
  1. Inflammation4▲ 8.2×22 topics
  2. Statins4▲ 218×2 topics
  3. Clinical Trials4▲ 23×5 topics
  4. Cardiovascular Disease Prevention4▲ 163×2 topics
  5. C-Reactive Protein4▲ 184×2 topics
  6. Cholesterol-lowering3▲ 293×1 topic
  7. LDL Cholesterol3▲ 395×1 topic
  8. Atherosclerosis3▲ 44×6 topics
  9. Cardiovascular Disease3▲ 10.0×9 topics
  10. Metabolic Syndrome3▲ 14×9 topics
  11. Cholesterol2▲ 68×3 topics
  12. Insulin Resistance2▲ 20×5 topics
  13. Obesity2▲ 10×7 topics
  14. Diabetes2▲ 14×4 topics
  15. Oxidative Stress2▲ 3.6×7 topics
  16. Cancer1▲ 3.7×8 topics
  17. Autoantibodies1▲ 20×2 topics
  18. Glucose Metabolism1▲ 47×2 topics
  19. Metabolism1▲ 8.9×4 topics
  20. Antiphospholipid Syndrome1▲ 90×1 topic
  21. Cardiovascular Risk1▲ 13×5 topics
  22. Global Prevalence1▲ 44×1 topic
  23. Lifestyle Intervention1▲ 48×1 topic
  24. Systemic Lupus Erythematosus1▲ 80×1 topic
  25. Macrophage1▲ 52×2 topics
  26. Prognostic Factors1▲ 9.3×3 topics
  27. Quality of Life1▲ 2.8×2 topics

Which research topics does Esperion Therapeutics (United States) publish most on?

By volume in 2022-now: Lipoproteins and Cardiovascular Health, Systemic Lupus Erythematosus Research, Diabetes, Cardiovascular Risks, and Lipoproteins and Cancer Treatment and Pharmacology.

  1. 1 Lipoproteins and Cardiovascular Health Surgery 3 works
  2. 2 Systemic Lupus Erythematosus Research Rheumatology 1 works
  3. 3 Diabetes, Cardiovascular Risks, and Lipoproteins Endocrinology, Diabetes and Metabolism 1 works
  4. 4 Cancer Treatment and Pharmacology Oncology 1 works
  5. 5 Chronic Lymphocytic Leukemia Research Genetics 1 works
  6. 6 Cholesterol and Lipid Metabolism Surgery 1 works
  7. 7 Cancer, Lipids, and Metabolism Cancer Research 1 works
  8. 8 HIV-related health complications and treatments Emergency Medicine 1 works
  9. 9 Atherosclerosis and Cardiovascular Diseases Immunology 0 works
  10. 10 Liver Disease Diagnosis and Treatment Epidemiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available44.1%not open55.9%

World: 40% of research is openly available.

with international co-authors33.2%domestic only66.8%

World: 18% is written across borders.

How has Esperion Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 79% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Esperion Therapeutics (United States) as a percentage of every work published that year, 0.000065% in 2024.

still counting0.00010%0.00020%0.00030%Esperion Therapeutics (United States)0.000090% in 2025200020102020

Fractional works of Esperion Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Ann Arbor

All research institutions in Ann Arbor

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Esperion Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.